Bayers, Pipeline

Bayer's Pipeline Delivers Two Approvals While Analysts Weigh the Upside

Published on 11/17/2026 at 03:40 | Editorial boerse-global.de
Bayer gained FDA clearance for stroke drug SUNHARBO and Chinese approval for lung cancer therapy Sevabertinib, but analyst targets remain divided.
Bayers, Pipeline, Delivers, Two, Approvals, While, Analysts, Weigh, Upside, Bayer Illustration mit AI erstellt.

Bayer has secured regulatory clearance on two fronts within days of each other, winning Chinese approval for a lung cancer therapy and US backing for a first-in-class stroke medicine — a twin win that has done little to shift the divide among the analysts who cover the stock.

The more recent green light came from the FDA, which in November authorised Asundexian under the brand name SUNHARBO. The drug is cleared for certain adults who have suffered a non-cardioembolic ischaemic stroke or a high-risk transient ischaemic attack, and is indicated in combination with antiplatelet therapy to lower the risk of further strokes. Bayer describes it as the first approved factor XIa inhibitor.

Efficacy data underpinning the decision come from the Phase III OCEANIC-STROKE trial, in which the company says treatment cut ischaemic strokes by 26%. That figure reflects the study outcome; the approved label itself stays confined to the patient group and combination regimen outlined above.

Jefferies Sees No Surprise, Deutsche Bank Turns More Bullish

Jefferies treated the US clearance as par for the course. Analyst Michael Leuchten, writing on 10 November, kept Bayer at "Hold" with a price target of EUR 48.50 — neither raising his valuation nor altering his rating in response to the approval.

Should investors sell immediately? Or is it worth buying Bayer?

Deutsche Bank moved the other way the same day, lifting its target to EUR 65 from EUR 60 while reaffirming its Buy recommendation. The Frankfurt-based lender had already flagged the stronger pharmaceuticals division and higher earnings estimates as the drivers behind the upgrade, with analyst Virginie Boucher-Ferte marking up her EBITDA and earnings-per-share forecasts for 2027 and 2028.

Bayer shares closed yesterday at EUR 56.80, placing the stock squarely between the two houses' targets.

China Clears Sevabertinib for First-Line Use

Four days before the US decision, on 4 November, Bayer obtained approval in China for Sevabertinib as a first-line treatment. The indication covers adults with advanced, HER2-mutated non-small cell lung cancer, extending the drug's use to the front line of care for that specific population.

Bayer at a turning point? This analysis reveals what investors need to know now.

Guidance Raised Despite Red Ink on the Bottom Line

The approvals landed alongside third-quarter 2026 results published on 3 November. Revenue for the period reached EUR 10.1 billion, and Bayer raised its full-year outlook for EBITDA before special items and for free cash flow, while also lifting margin expectations for its Pharmaceuticals division.

Profitability at the reported level told a different story. EBITDA before special items came in at EUR 1.62 billion, but the group posted a net loss of EUR 672 million and negative free cash flow of EUR 293 million. Net financial debt stood at EUR 31.1 billion, and management has signalled a reduction in that figure going forward; the improved free cash flow guidance applies to the full year.

Ad

Bayer Stock: New Analysis - 17 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70524007 |